CRIS
Curis Inc
stockNASDAQ
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis's pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.40 | 2026-10-27 | +102.96% | 2.308 |
| 1M | 0.80 | 2026-10-02 | +1.68% | -1.205 |
| 3M | 5.15 | 2026-08-03 | -84.14% | -0.402 |
| 6M | 0.58 | 2026-05-04 | +40.65% | 19.598 |
| 1Y | 1.48 | 2025-11-03 | -44.80% | 10.046 |
| 2Y | 4.33 | 2024-11-04 | -81.13% | — |
| 5Y | 138.40 | 2021-11-03 | -99.41% | 1.965 |
Curis Inc (NASDAQ:CRIS) stock price today is $0.82, and today's volume is 26,482,914. CRIS is up 23.585% today. The 30 day average volume is 506,875. CRIS market cap is $1.98M with 2.43M shares outstanding.